Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Swanton

Showing results (101-110 of 439) with videos related to

Pageof 44
Sort By:
The EPMA Journal|June 29, 2012
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?Timothy A Yap, Charles Swanton, Johann S de Bono
Cold Spring Harbor Perspectives in Medicine|March 15, 2017
Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer EvolutionSubramanian Venkatesan, Charles Swanton, Barry S Taylor, et al.
Current Opinion in Urology|July 1, 2015
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?Aspasia Soultati, Mark Stares, Charles Swanton, et al.
Cancer Discovery|June 21, 2015
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and HeterogeneityCharles Swanton, Nicholas McGranahan, Gabriel J Starrett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2015
Translational implications of tumor heterogeneityMariam Jamal-Hanjani, Sergio A Quezada, James Larkin, et al.
Genome Biology|September 16, 2014
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineCrispin Hiley, Elza C de Bruin, Nicholas McGranahan, et al.
Current Biology : CB|February 22, 2014
Response to Bakhoum et alRebecca A Burrell, Sarah E McClelland, Jiri Bartek, et al.
Cell Cycle (Georgetown, Tex.)|August 28, 2007
Initiation of high frequency multi-drug resistance following kinase targeting by siRNAsCharles Swanton, Barbara Nicke, Michela Marani, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 17, 2023
Clonal Evolution in Healthy and Premalignant Tissues: Implications for Early Cancer Interception StrategiesJayant K Rane, Alexander M Frankell, Clare E Weeden, et al.
The Lancet. Oncology|August 8, 2015
Relapse models for clear cell renal carcinomaSakshi Gulati, Samra Turajlic, James Larkin, et al.
Pageof 44

Showing results (101-110 of 439) with videos related to

Sort By:
Pageof 44
The EPMA Journal|June 29, 2012
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?Timothy A Yap, Charles Swanton, Johann S de Bono
Cold Spring Harbor Perspectives in Medicine|March 15, 2017
Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer EvolutionSubramanian Venkatesan, Charles Swanton, Barry S Taylor, et al.
Current Opinion in Urology|July 1, 2015
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?Aspasia Soultati, Mark Stares, Charles Swanton, et al.
Cancer Discovery|June 21, 2015
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and HeterogeneityCharles Swanton, Nicholas McGranahan, Gabriel J Starrett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2015
Translational implications of tumor heterogeneityMariam Jamal-Hanjani, Sergio A Quezada, James Larkin, et al.
Genome Biology|September 16, 2014
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicineCrispin Hiley, Elza C de Bruin, Nicholas McGranahan, et al.
Current Biology : CB|February 22, 2014
Response to Bakhoum et alRebecca A Burrell, Sarah E McClelland, Jiri Bartek, et al.
Cell Cycle (Georgetown, Tex.)|August 28, 2007
Initiation of high frequency multi-drug resistance following kinase targeting by siRNAsCharles Swanton, Barbara Nicke, Michela Marani, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 17, 2023
Clonal Evolution in Healthy and Premalignant Tissues: Implications for Early Cancer Interception StrategiesJayant K Rane, Alexander M Frankell, Clare E Weeden, et al.
The Lancet. Oncology|August 8, 2015
Relapse models for clear cell renal carcinomaSakshi Gulati, Samra Turajlic, James Larkin, et al.
Pageof 44